GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (GMI), a privately held firm that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced it has been selected to give an oral presentation of new results of its lead drug candidate in animal models of vaso-occlusive crisis of sickle cell disease at the 50th Annual American Society of Hematology (ASH) meeting, December 6th-9th in San Francisco.
